147 related articles for article (PubMed ID: 35063138)
1. Post-stroke treatment with K-134, a phosphodiesterase 3 inhibitor, improves stroke outcomes in the stroke-prone spontaneously hypertensive rat model-A comparative evaluation of antiplatelet drugs.
Yoshida H; Itoh S; Ferdousi F; Isoda H
J Pharmacol Sci; 2022 Feb; 148(2):229-237. PubMed ID: 35063138
[TBL] [Abstract][Full Text] [Related]
2. K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model.
Yoshida H; Ashikawa Y; Itoh S; Nakagawa T; Asanuma A; Tanabe S; Inoue Y; Hidaka H
PLoS One; 2012; 7(10):e46432. PubMed ID: 23110051
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet Therapy in Cerebral Small Vessel Disease.
Bouasquevisque DS; Benavente OR; Shoamanesh A
Curr Neurol Neurosci Rep; 2019 Jul; 19(9):61. PubMed ID: 31352655
[TBL] [Abstract][Full Text] [Related]
4. K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models.
Sasaki Y; Suzuki H; Itoh S; Yoshida H; Kondo S; Inoue K; Tanabe S
Eur J Pharmacol; 2012 Aug; 689(1-3):132-8. PubMed ID: 22659587
[TBL] [Abstract][Full Text] [Related]
5. A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
Yoshida H; Itoh S; Hara T; Sasaki Y; Kondo S; Nakagawa T; Asanuma A; Tanabe S
Atherosclerosis; 2012 Mar; 221(1):84-90. PubMed ID: 22269153
[TBL] [Abstract][Full Text] [Related]
6. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial.
Al-Shahi Salman R; Minks DP; Mitra D; Rodrigues MA; Bhatnagar P; du Plessis JC; Joshi Y; Dennis MS; Murray GD; Newby DE; Sandercock PAG; Sprigg N; Stephen J; Sudlow CLM; Werring DJ; Whiteley WN; Wardlaw JM; White PM;
Lancet Neurol; 2019 Jul; 18(7):643-652. PubMed ID: 31129065
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Kwan J; Hafdi M; Chiang LLW; Myint PK; Wong LS; Quinn TJ
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012269. PubMed ID: 35833913
[TBL] [Abstract][Full Text] [Related]
8. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH;
Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356
[TBL] [Abstract][Full Text] [Related]
9. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Toyoda K; Uchiyama S; Hoshino H; Kimura K; Origasa H; Naritomi H; Minematsu K; Yamaguchi T;
Int J Stroke; 2015 Feb; 10(2):253-8. PubMed ID: 25487817
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of plant oils on the cerebral hemorrhage in stroke-prone spontaneously hypertensive rats.
Cai J; Jang JY; Kim J; Shin K; Kim KS; Park D; Kim TS; Lee SP; Ahn B; Choi EK; Lee J; Kim YB
Nutr Neurosci; 2016 Sep; 19(7):318-26. PubMed ID: 24856006
[TBL] [Abstract][Full Text] [Related]
11. Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
Tanaka N; Katayama Y; Katsumata T; Otori T; Nishiyama Y
Brain Res; 2007 Sep; 1169():125-32. PubMed ID: 17706949
[TBL] [Abstract][Full Text] [Related]
12. P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis.
Huang WY; Ovbiagele B; Lee M
J Formos Med Assoc; 2022 Jun; 121(6):1053-1061. PubMed ID: 34426033
[TBL] [Abstract][Full Text] [Related]
13. Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosis.
Tomizawa A; Ohno K; Jakubowski JA; Mizuno M; Sugidachi A
Thromb Res; 2015 Dec; 136(6):1224-30. PubMed ID: 26388120
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention.
Luo L; Fu M; Li Y; Chen Z; Yu J; Luo J; Hu S; Tu L; Xu X
Clin Cardiol; 2020 Mar; 43(3):235-241. PubMed ID: 31777973
[TBL] [Abstract][Full Text] [Related]
15. Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats.
Guan J; Clermont AC; Pham LD; Ustunkaya T; Revenko AS; MacLeod AR; Feener EP; Simão F
Transl Stroke Res; 2022 Apr; 13(2):287-299. PubMed ID: 34241810
[TBL] [Abstract][Full Text] [Related]
16. Alterations of lymphocyte count and platelet volume precede cerebrovascular lesions in stroke-prone spontaneously hypertensive rats.
Nishinaka T; Yamazaki Y; Niwa A; Wake H; Mori S; Yoshino T; Nishibori M; Takahashi H
Biomarkers; 2020 May; 25(3):305-313. PubMed ID: 32285702
[No Abstract] [Full Text] [Related]
17. Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials.
Verdoia M; Savonitto S; Dudek D; Kedhi E; De Luca G
Vascul Pharmacol; 2021 Apr; 137():106828. PubMed ID: 33385541
[TBL] [Abstract][Full Text] [Related]
18. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
19. Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke.
Shimazawa M; Hara H
J Pharmacol Sci; 2011; 116(1):30-5. PubMed ID: 21498958
[TBL] [Abstract][Full Text] [Related]
20. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Kamran H; Jneid H; Kayani WT; Virani SS; Levine GN; Nambi V; Khalid U
JAMA; 2021 Apr; 325(15):1545-1555. PubMed ID: 33877270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
